NeoGenomics, Inc. — Q1 2023 Form 10-Q
Business and period: The company operates cancer-focused clinical testing laboratories and provides testing, research, clinical-trial and informatics services to pharmaceutical companies. This unaudited report covers the three months ended March 31, 2023; comparisons are with Q1 2022 unless otherwise noted. Dollar amounts below are in millions unless specified.
Financial performance
| Metric | Q1 2023 | Q1 2022 |
|---|---|---|
| Revenue | $137.2 | $117.2 |
| Gross profit / margin | $54.8 / 39.9% | $38.2 / 32.6% |
| Operating expenses | $89.9 | $90.3 |
| Operating loss | $(35.1) | $(52.0) |
| Net loss | $(30.8) | $(49.4) |
| Diluted loss per share | $(0.25) | $(0.40) |
| Adjusted EBITDA (non-GAAP) | $(7.1) | $(19.0) |
| Cash used in operating activities | $(12.7) | $(29.0) |
- Revenue by segment: Clinical Services revenue was $114.9 million, up 16.3%; Pharma Services revenue was $22.4 million, up 21.6%. Management attributed Clinical growth to higher test volume, favorable test mix and higher average unit pricing from reimbursement initiatives; Pharma growth reflected project timing.
- Margins and expenses: Gross margin rose 7.3 percentage points. Cost of revenue increased 4.4%, slower than revenue growth. G&A fell 7.1%, partly because Q1 2022 included $5.9 million of incremental stock compensation from accelerated vesting after the CEO’s departure. Q1 2023 included $4.7 million of restructuring charges.
- Liquidity: At March 31, cash and cash equivalents were $275.6 million and marketable securities were $142.3 million. Working capital was $498.4 million. Cash increased $12.4 million during the quarter, reflecting $23.7 million of investing cash inflows and $1.4 million of financing inflows, offset in part by operating cash use.
- Debt: Convertible notes, net, totaled $536.0 million on the balance sheet. Principal amounts are $201.3 million of 1.25% notes due 2025 and $345.0 million of 0.25% notes due 2028. Neither series met its conversion price condition for holder conversion in Q2 2023. The if-converted value did not exceed principal at the March 31 stock price.
Changes, outlook and risks
- Net loss improved by $18.6 million year over year, while revenue increased 17.1% and gross profit increased 43.4%. The company remained loss-making, and operating cash flow remained negative.
- Management said available cash, marketable securities and expected collections should fund near-term operating and capital needs for at least 12 months. It forecast 2023 capital expenditures of $30–$40 million; $9.9 million was spent in Q1.
- The restructuring program is expected to continue through 2023, with approximately $3.0 million of additional charges anticipated and activities expected to finish by December 31, 2023. Management also expects R&D spending to increase as it invests in new tests; higher sales commissions are expected in coming quarters.
- No revenue or earnings guidance is provided in the supplied filing text. Management’s stated 2023 priorities include profitable core growth, NGS and liquid-biopsy initiatives, Pharma Services growth and improved profitability.
- Contingencies: An ongoing federal healthcare regulatory investigation involves consulting and service agreements; the company recorded an $11.2 million reserve and could not estimate additional loss exposure. DOJ participation was disclosed. Patent litigation brought by Natera and a shareholder securities class action remain unresolved; outcomes were described as not estimable or probable. The company also recorded a liability for a separate dispute in pre-litigation mediation, but the amount is not clearly stated in the filing text.
- Other risks: The filing highlights reimbursement pressure, payer denials and billing, regulation of laboratory-developed tests, debt service and potential dilution, litigation and regulatory exposure, competition, execution of restructuring and growth plans, and foreign-currency and interest-rate risks. Management reported disclosure controls were effective at a reasonable-assurance level and no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether revenue growth and gross-margin improvement continue, and whether the company can reduce operating losses and achieve positive operating cash flow.
- Actual restructuring costs and savings, capital expenditures, and progress on management’s growth and profitability initiatives.
- Cash burn, marketable-security liquidity and ability to fund operations and capital needs; note maturities and any refinancing, repayment or dilution implications.
- Developments in the OIG/DOJ matter, including whether reserves increase, and outcomes or potential costs in the patent, securities and mediation matters.
- Reimbursement trends, payer collections and denials, and performance of clinical-trial activity and Pharma Services projects.